Matthew J. Sill

Matthew J. Sill focuses his practice on pharmaceutical and medical device mass torts, catastrophic personal injury, wrongful death, and class action litigation. He is frequently selected for leadership positions among large groups of attorneys representing hundreds or thousands of injured parties. Matt currently represents over 75 cities, counties, and tribes in the nationwide opioid litigation, In Re: National Prescription Opiate Litigation, MDL No. 2804, Case No. 17-md-02804. Matt also recently filed the first case in Oklahoma regarding the marketing and sale of JUUL, In Re: Juul Labs, Inc. Marketing, Sales Practices, and Product Liability Litigation. 

Matt regularly accepts invitations for faculty positions and speaking engagements at seminars and continuing legal education programs. He has lectured in numerous locations, including Arizona, Florida, Georgia, Illinois, Louisiana, New York, Oklahoma, Puerto Rico, and Texas, with programs typically being attended by lawyers from several other jurisdictions. He was chosen to co-chair HarrisMartin Publishing’s 2013 CAT Flood and Windstorm Litigation Conference. In the practice area of pharmaceutical and medical device litigation, Matt has been a featured instructor or moderator at educational programs devoted to Actos®, GranuFlo®, Topamax®, pre-emption in generic drug cases, and several other topics. He authors a number of articles, and up-to-date information on relevant publications and published legal opinions are available by request from admin@fulmersill.com.

Representing plaintiffs with cases pending in several different jurisdictions, Matt’s ability to practice pro hac vice is often based on the recommendation and sponsorship of local attorneys. See; e.g., MDL 2244, In Re: DePuy Hip Implant Litigation; MDL 2738, In Re: Johnson & Johnson Talcum Powder Products Liability Litigation. He is fully admitted to practice in the State of Oklahoma (2007), where out-of-state lawyers often retain him as local counsel for high-profile matters ranging from product liability to securities and antitrust. See; e.g., In Re: Chesapeake Energy Derivative Litigation. Matt has successfully helped families and individuals involved in opioid litigation, diabetes drug litigation, birth control litigation, gadolinium-based contrast dye litigation, hip replacement litigation, fentanyl pain patch litigation, heart defibrillator lead litigation, Las Vegas hepatitis litigation, Chinese drywall litigation, hormone replacement therapy litigation, denture cream litigation, heart surgery products litigation, dialysis products litigation, and aircraft crash litigation, to mention only a few.

Education

Prior to attending law school, Matt worked for a well-known talent and literary agency in Beverly Hills, Calif., and as a campaign official in a successful gubernatorial race in Oklahoma. As a law student, he consistently worked as a clerk to the senior partner of a high-profile mass tort firm in Los Angeles.

• Bachelor’s Degree in Business Administration University of Oklahoma 2009
• Juris Doctorate Whittier College 2005

Leadership

Matt was designated to serve in official leadership roles by presiding judges in the following matters:

Co-Lead Counsel for MDL 2700, In Re: Genentech, Inc., Herceptin (Trastuzumab) Marketing and Sales Practices Litigation, currently pending in United States District Court for the Northern District of Oklahoma.

Plaintiffs’ Steering Committee for MDL 2331, In Re: Propecia (Finasteride) Products Liability Litigation, currently pending in United States District Court for the Eastern District of New York Plaintiffs’ Steering Committee for JCCP 4749, In Re: GranuFlo and NaturaLyte Litigation, currently pending in Los Angeles Superior Court; Appellate Liaison Counsel and State Court Liaison Counsel for MDL 2266, In Re: Darvon, Darvocet, and Propoxyphene Products Liability Litigation, in which Matt was previously a member of Plaintiffs’ Executive Committee, currently pending in United States District Court for the Eastern District of Kentucky; and Class Counsel in Garcia v. Allergan, Case No. 11-cv-9811 PSG, in which physicians throughout the United States received settlement funds for purchasing Botox Cosmetic based on off-label promotion, currently pending in United States District Court for the Central District of California.

Matt was also instrumental in fulfilling his firm’s co-lead counsel responsibilities for the BOK National Settlement Class from MDL 2036, In Re: Checking Account Overdraft Litigation, and Plaintiffs’ Steering Committee (“PSC”) duties for MDL 1871, In Re: Avandia Sales Marketing and Products Liability Litigation. He was also on the trial team in Bergen County, N.J., for Stribling v. Wyeth, the last successful (from a plaintiff’s perspective) “fen-phen” verdict in the United States. Over the past decade, Matt’s firm has represented the largest number of “fen-pen” claimants in the nation. His team currently assists with PSC obligations in the multibillion-dollar global settlement program of MDL 2299, In Re: Actos Products Liability Litigation, the largest single mass tort settlement involving a drug that’s still on the market.

In multiple matters before the United States Court of Appeals for the Sixth Circuit and the United States Court of Appeals for the Ninth Circuit, Matt represented hundreds of people allegedly injured or killed by generic prescription drugs. See; e.g., Romo v. Teva Pharmaceuticals USA, Inc. He also appeared before the United States Court of Appeals for the Tenth Circuit on behalf of several hundred women bringing claims against vaginal mesh manufacturers. See; e.g., Teague et al. v. Johnson & Johnson et al.